COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,724 Articles (22,913 medRxiv, 8,811 bioRxiv)

Most recent first Previous |  Page 250: Articles 2491-2500  | Next

COVID-19 mass testing in adult social care in England
Chen, S., Creswell, R., Hounsell, R., Cantrell, L., Bajaj, S., Dahal, P., Tsui, L. H., Kolade, O., Amswych, M., Naidoo, R., Fowler, T., Hopkins, S., Stepniewska, K., Voysey, M., White, L. J., Shretta, R., Lambert, B., EY-Oxford Health Analytics Consortium
10.1101/2024.06.06.24308563 — Posted: 2024-06-07
Sleep Quality mediates the association between Tea Consumption and Duration of COVID-19-related Symptoms in the Elderly
Fan, Y., Wang, Y., Jiang, J., Yang, S., Lu, J., Ma, Q., Zhu, H.
10.1101/2024.06.06.24308573 — Posted: 2024-06-07
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
Gentile, I., Giaccone, A., Scirocco, M. M., Di Brizzi, F., Cuccurullo, F., Silvitelli, M., Ametrano, L., Alfe, F. A., Pietroluongo, D., Irace, I., Chiariello, M., De Felice, N., Severino, S., Viceconte, G., Schiano Moriello, N., Maraolo, A. E., Buonomo, A. R., Scotto, R., Federico II COVID team
10.1101/2024.06.07.24307681 — Posted: 2024-06-07
A Nanobody Interaction with SARS-CoV-2 Spike Allows the Versatile Targeting of Lentivirus Vectors
Alfadhli, A., Bates, T. A., Barklis, R. L., Romanaggi, C., Tafesse, F., Barklis, E.
10.1101/2024.06.06.597774 — Posted: 2024-06-07
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
Yu, L., Wang, Y., Liu, Y., Xing, X., Li, C., Wang, X., Shi, J., Ma, W., Li, J., Chen, Y., Qiao, R., ZHAO, X., Gao, M., Wen, S., Xue, Y., Guan, Y., Chu, H., Sun, L., Wang, P.
10.1101/2024.06.06.597720 — Posted: 2024-06-07
Serum anti-nucleocapsid antibody level induced after primary infection is an immunological surrogate of protection against SARS-CoV-2 re-infection in hybrid immunity holders
Miyamoto, S., Numakura, K., Kinoshita, R., Arashiro, T., Takahashi, H., Hibino, H., Hayakawa, M., Kanno, T., Sataka, A., Ainai, A., Arai, S., Suzuki, M., Yoneoka, D., Wakita, T., Suzuki, T.
10.1101/2024.06.05.24308479 — Posted: 2024-06-06
Exploring the Gender Gap in Young Adult Mental Health during COVID-19: Evidence from the UK
Webster, M., Manoukian, S., McKendrick, J. H., Biosca, O.
10.1101/2024.06.05.24308512 — Posted: 2024-06-06
Characterizing Public Sentiments and Drug Interactions during COVID-19: A Pretrained Language Model and Network Analysis of Social Media Discourse
Li, W., Hua, Y., Zhou, P., Li, Z., Xu, X., Yang, J.
10.1101/2024.06.06.24308537 — Posted: 2024-06-06
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity -- IVY Network, 26 Hospitals, October 18, 2023-March 9, 2024
Ma, K. C., Surie, D., Lauring, A. S., Martin, E. T., Leis, A. M., Papalambros, L., Gaglani, M., Columbus, C., Gottlieb, R. L., Ghamande, S., Peltan, I. D., Brown, S. M., Ginde, A. A., Mohr, N. M., Gibbs, K. W., Hager, D. N., Saeed, S., Prekker, M. E., Gong, M. N., Mohamed, A., Johnson, N. J., Srinivasan, V., Steingrub, J. S., Khan, A., Hough, C. L., Duggal, A., Wilson, J. G., Qadir, N., Chang, S. Y., Mallow, C., Kwon, J. H., Parikh, B., Exline, M. C., Vaughn, I. A., Ramesh, M., Safdar, B., Mosier, J., Harris, E. S., Shapiro, N. I., Felzer, J., Zhu, Y., Grijalva, C. G., Halasa, N., Chappell, J.
10.1101/2024.06.04.24308470 — Posted: 2024-06-05
Competing Risk Survival analysis of time to in-hospital mortality or Recovery among Covid-19 Patients in South-East Ethiopia: a hospital-based multisite study
Demissie, A., Wordofa, A., Kalu, A., Tune, A., Suleiman, M., Kibret, A., Abera, Z., Mulugeta, Y.
10.1101/2024.06.04.24308446 — Posted: 2024-06-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).